- In March 2025, AstraZeneca is showcasing innovation in infectious disease protection, presenting preclinical data on investigational monoclonal antibodies (mAbs) targeting high-priority pathogens such as Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae. These targeted therapies aim to combat serious bacterial infections and address antimicrobial resistance
- In February 2025, New phase 3 randomized controlled trials (EAGLE-2 and EAGLE-3) published in February 2024 tested gepotidacin, an oral, first-in-class triazaacenaphthylene antibiotic, for uncomplicated urinary tract infections. Gepotidacin was noninferior to nitrofurantoin in EAGLE-2 and superior in EAGLE-3.
- In January 2025, A major breakthrough in HIV prevention was highlighted, with a twice-yearly injectable lenacapavir showing high efficacy. FDA approval for this game-changing intervention is anticipated
- In January 2025, Research on ridinilazole, a novel bis-benzimidazole antibiotic, for Clostridioides difficile infections (CDI) in Phase 3 trials showed it selectively kills C. difficile while preserving gut microbiota. While not superior to vancomycin in sustained clinical response, it had a significantly lower recurrence rate
- In May 2023, The FDA approved sulbactam-durlobactam (Xacduro) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex. This addresses a critical need for new drugs against resistant Gram-negative bacteria
